CLINICAL TRIALS PROFILE FOR NALOXONE

505(b)(2) Clinical Trials for Naloxone

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00637000 ↗	Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone	Completed	Indivior Inc.	Phase 2	2008-03-01	The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or buprenorphine/naloxone in persons with active opioid dependence. The primary outcome measure is the severity of withdrawal symptoms measured using the Clinical Opiate Withdrawal Scale (COWS). The primary study hypothesis is that neither drug formulation will precipitate an opioid withdrawal syndrome.
OTC	NCT02137213 ↗	Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation	Completed	Academic Health Science Centres	Phase 2	2014-08-01	At least 30% of patients receiving methadone maintenance therapy (MMT) are suffering from constipation that often affects effectiveness of MMT and increases its impact on health care system. Existing treatments include several over-the-counter medications which do not target the pathobiological basis of opioid-induced constipation and have limited effectiveness. At the same time well-known medication, naloxone, was already shown to help with constipation in patients receiving methadone for chronic pain, but was never tried in patients receiving methadone for opioid dependence. This study is aimed to try naloxone for treatment of opioid-induced constipation in MMT settings. The investigators will enroll 20 patients receiving MMT and suffering from opioid-induced constipation. The study has a crossover design - all patients will receive one week of their regular methadone doses and one week of their regular methadone doses with naloxone added. Normal saline will be added to methadone-only formulations as placebo. Order of the weeks will be chosen randomly. Both subjects and investigators will be blinded to the study condition (i.e. whether naloxone or normal saline is added to methadone preparation on a given week). Primary hypothesis: Patients receiving combination of oral methadone/naloxone in ratio 50:1 will have less severe symptoms of constipation compared to those receiving methadone only. Secondary hypothesis: Addition of oral naloxone to methadone in a ratio 50:1 will not cause clinically significant opioid withdrawal symptoms.
OTC	NCT02137213 ↗	Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation	Completed	Centre for Addiction and Mental Health	Phase 2	2014-08-01	At least 30% of patients receiving methadone maintenance therapy (MMT) are suffering from constipation that often affects effectiveness of MMT and increases its impact on health care system. Existing treatments include several over-the-counter medications which do not target the pathobiological basis of opioid-induced constipation and have limited effectiveness. At the same time well-known medication, naloxone, was already shown to help with constipation in patients receiving methadone for chronic pain, but was never tried in patients receiving methadone for opioid dependence. This study is aimed to try naloxone for treatment of opioid-induced constipation in MMT settings. The investigators will enroll 20 patients receiving MMT and suffering from opioid-induced constipation. The study has a crossover design - all patients will receive one week of their regular methadone doses and one week of their regular methadone doses with naloxone added. Normal saline will be added to methadone-only formulations as placebo. Order of the weeks will be chosen randomly. Both subjects and investigators will be blinded to the study condition (i.e. whether naloxone or normal saline is added to methadone preparation on a given week). Primary hypothesis: Patients receiving combination of oral methadone/naloxone in ratio 50:1 will have less severe symptoms of constipation compared to those receiving methadone only. Secondary hypothesis: Addition of oral naloxone to methadone in a ratio 50:1 will not cause clinically significant opioid withdrawal symptoms.
New Formulation	NCT02158117 ↗	Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use	Completed	St. Olavs Hospital	Phase 1	2014-03-01	Overdose with potential deadly outcome is a serious problem among opioid abusers, not least in Norway. The annual death toll from overdose is about 250, twice the annual death toll from traffic accidents. Those who inject heroin or other opioids are considered to have the highest risk for death from overdose. To save lives, immediate treatment with a μ-opioid antidote such as naloxone is required. Usually naloxone is injected into a muscle or a blood vessel. Administration of naloxone via the nose has been suggested as an alternative for use by emergency teams and possibly also bystanders. This is not only an easier way to give naloxone, but would also eliminate the risk for needle stick injuries and blood contamination. A pilot study in this hospital has shown no significant side effects or adverse reaction. While significant benefits are expected from developing an adequately formulated naloxone nasal spray for pre-hospital use, the risks to participants are minimal. Therefore this preclinical study in healthy volunteers will be undertaken.

All Clinical Trials for Naloxone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000192 ↗	Neurobiology of Opioid Dependence: 1 - 1	Withdrawn	National Institute on Drug Abuse (NIDA)	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.
NCT00000192 ↗	Neurobiology of Opioid Dependence: 1 - 1	Withdrawn	Yale University	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.
NCT00000193 ↗	Neurobiology of Opioid Dependence: 2 - 2	Withdrawn	National Institute on Drug Abuse (NIDA)	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.
NCT00000193 ↗	Neurobiology of Opioid Dependence: 2 - 2	Withdrawn	Yale University	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.

Clinical Trial Conditions for Naloxone

Condition Name

Condition Name for Naloxone
Intervention	Trials
Opioid-Related Disorders	41
Pain	29
Opioid Use Disorder	27
Opioid Dependence	21

Condition MeSH

Condition MeSH for Naloxone
Intervention	Trials
Opioid-Related Disorders	130
Substance-Related Disorders	36
Disease	20
Constipation	18

Clinical Trial Locations for Naloxone

Trials by Country

Trials by Country for Naloxone
Location	Trials
United States	491
China	24
Canada	23
Norway	14
Germany	12

Trials by US State

Trials by US State for Naloxone
Location	Trials
New York	43
Maryland	37
California	37
Massachusetts	23
Pennsylvania	19

Clinical Trial Progress for Naloxone

Clinical Trial Phase

Clinical Trial Phase for Naloxone
Clinical Trial Phase	Trials
PHASE4	8
PHASE3	5
PHASE2	3

Clinical Trial Status

Clinical Trial Status for Naloxone
Clinical Trial Phase	Trials
Completed	211
Recruiting	51
Not yet recruiting	39

Clinical Trial Sponsors for Naloxone

Sponsor Name

Sponsor Name for Naloxone
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	70
Indivior Inc.	14
Johns Hopkins University	13

Sponsor Type

Sponsor Type for Naloxone
Sponsor	Trials
Other	368
Industry	131
NIH	84

Clinical Trials Update, Market Analysis, and Projection for Naloxone

Last updated: January 29, 2026

Summary

Naloxone, an opioid antagonist integral to reversing opioid overdose, has experienced transformative growth driven by escalating opioid-related mortality. This report synthesizes recent clinical trial developments, current market dynamics, and future projections, providing actionable insights for stakeholders in pharmaceutical, healthcare, and policy sectors.

---

What Are Recent Clinical Trial Developments for Naloxone?

Key Clinical Trials and Regulatory Milestones (2022–2023)

Year	Trial Name/ID	Purpose	Status	Findings	References
2022	NCT05287937	Evaluate intranasal naloxone efficacy in diverse populations	Ongoing	Preliminary data show increased efficacy in rapid overdose reversal	[1]
2022	NCT04450489	Assess the safety of naloxone autoinjectors in emergency use	Completed	No significant adverse events, high user acceptability	[2]
2023	NCT05826056	Investigate nasal delivery devices for ease of use	Ongoing	Early results indicate quicker administration times	[3]
2023	FDA Post-Marketing Surveillance	Monitor real-world safety of naloxone products	Ongoing	Consistent safety profile observed	[4]

Focus Areas in Trials

• Alternative Delivery Systems: Exploring intranasal gels, auto-injectors, and inhalers to facilitate rapid administration.
• Expanded Indications: Including prophylactic use in high-risk populations.
• Formulation Improvements: Enhancing bioavailability and shelf stability.
• Diverse Populations: Testing efficacy among pediatric, pregnant, and elderly cohorts.

Regulatory Outlook

The FDA recently approved nasal spray formulations with improved absorption profiles. Efforts continue to gain approvals internationally, notably in European and Asian markets, with clinical data supporting broad safety and efficacy.

---

Market Analysis of Naloxone

Current Market Size

Region	2022 Revenue (USD millions)	Market Share (%)	Growth Rate (CAGR, 2023–2027)
North America	950	65%	8%
Europe	270	18%	6.5%
Asia-Pacific	140	10%	12%
Rest of World	50	7%	9%

Source: IQVIA, 2023.

Key Market Drivers

• Rising Opioid Overdose Deaths: Over 100,000 annual deaths globally (WHO, 2021).
• Government Policies & Funding: USA's SOR program (Supporting Point of Dispensing) increased access in community settings.
• Increasing Awareness & Education: Campaigns like KnowNaloxone raise public and first responder awareness.
• Product Diversification: Development of user-friendly delivery devices enhances distribution channels.

Market Segments

Segment	Description	Market Share (%)	Main Players
Formulation	Intranasal sprays, auto-injectors, IM injectables	70%	Narcan (HHS), Evzio (Kaléo), G-Tec (generic)
Distribution Channel	Pharmacies, hospitals, community programs	60%, 25%, 15%	Major distributors include CVS, Walgreens, Medicaid programs
Patient Type	General population, high-risk groups	85%, 15%	Focus on community, first responders

Competitive Landscape

Company	Market Share (2023)	Key Innovations	R&D Focus
Kaléo	40%	Auto-injector technology	Long-acting formulations
HHS (US Government)	30%	Large-scale distribution	Cost reduction initiatives
Teva, Mylan (Generic manufacturers)	15–20%	Affordable nasal sprays	Bioequivalent formulations

---

Future Market Projections (2023–2028)

Projected Growth Figures

Year	Global Market Size (USD millions)	CAGR (%)	Remarks
2023	1,410	-	Baseline year
2024	1,620	15%	Increased adoption due to policy pushes
2025	1,850	14%	Expanded indications and new formulations
2026	2,120	14%	Entry into emerging markets
2027	2,420	14%	Enhancement of access strategies
2028	2,760	13.8%	Potential peak driven by policy saturation

Drivers of Growth

• Regulatory Approval of New Formulations: Emergency use authorization for alternatives (e.g., auto-injectors with simplified administration).
• Global Policy Adoption: WHO’s inclusion of naloxone in essential medicines lists (2021).
• Expanded Indications: Prophylactic applications for at-risk populations.
• Market Penetration in Asia-Pacific: Rapidly increasing prevalence of opioid misuse.

Potential Barriers

• Pricing and Reimbursement Policies: Impact on affordability in low- and middle-income countries.
• Supply Chain Constraints: Raw material shortages, manufacturing disruptions.
• Regulatory Variability: Differing approval timelines across jurisdictions.

---

Comparison of Naloxone Products

Product Name	Formulation	Administration Route	Market Approval Year	Key Features	Price (USD)
Narcan Nasal Spray	Gel-based nasal spray	Intranasal	2015 (FDA)	Easy to administer, approved for laypersons	~$130 (2-dose kit)
Evzio Auto-Injector	Auto-injector	Intramuscular	2014 (FDA)	Single-step auto-injection, trained use	~$600 (per dose)
Generic Nasal Sprays	Liquid nasal spray	Intranasal	2019 onwards	Cost-effective alternatives, off-patent	~$50–70
Harm Reduction Devices	Intranasal/injectable	Varies	Ongoing approvals	Emphasize community friendliness	Variable

---

FAQs

1. What are the main clinical benefits driving adoption of new naloxone formulations?

Innovations like intranasal sprays and auto-injectors facilitate rapid, easy administration by non-medical personnel, increasing overdose reversals, especially in community and emergency settings.

2. How are regulatory agencies influencing the market for naloxone?

The FDA’s expedited approvals, including over-the-counter (OTC) status for certain formulations, and global policies aiming to broaden access, significantly expand market penetration.

3. What are the primary regions expected to drive future market growth?

The United States remains the dominant market, but significant growth is anticipated in Europe and Asia-Pacific, driven by changing policies and rising opioid misuse.

4. How is recent clinical trial data impacting product development?

Data supporting efficacy in diverse populations and simplified delivery systems motivate manufacturers to develop next-generation formulations, expanding scope and user-friendliness.

5. What are the key factors that could hinder market growth?

Pricing disparities, reimbursement issues, supply chain disruptions, and regulatory hurdles in emerging markets pose potential risks.

---

Key Takeaways

• Clinical Progress: Ongoing trials focus on optimizing delivery, safety, and expanding indications, with recent FDA approvals emphasizing ease of use.
• Market Dynamics: Driven by rising opioid overdose mortality, government policies, and product innovations, the global naloxone market is poised for substantial growth.
• Market Outlook: The projection estimates a CAGR of approximately 14% from 2023 to 2028, with revenues surpassing USD 2.7 billion by 2028.
• Competitive Strategies: Companies investing in user-friendly devices, affordability, and global expansion will likely dominate the future landscape.
• Policy Impact: Increased regulatory support and inclusion in essential medicines lists will accelerate access and market adoption globally.

---

References

1. ClinicalTrials.gov, 2022-2023 Trials on Naloxone Delivery & Safety
2. FDA Approvals and Post-Market Surveillance Data, 2022-2023
3. IQVIA Report, 2023. Global Pharmacovigilance & Market Insights.
4. WHO, 2021. Global Status Report on Opioid Overdose.